Assessing TP53 status in human tumours to evaluate clinical outcome

By T. Soussi, C. Béroud. Nature Reviews. Cancer, 2001

744 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “Meanwhile, it has been demonstrated that loss of TP53 function decreased genomic stability and was associated with defects in DNA damage repair, indicating a higher mutational burden might occur in TP53 mutational tumor (18).”
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. (2009, neutral): “More than 80% of p53 alterations are missense mutations that lead to the synthesis of a stable but transcriptionally deficient protein (Soussi and Beroud, 2001).”
When mutants gain new powers: news from the mutant p53 field (2009, background): “In fact, immunohistochemical (IHC) detection of p53 in tumours usually indicates TP53 missense mutation and can provide prognostic and predictive informatio”
p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure–Function Continuum Concept (2016, background): “Proper functionality of the p53 DBD critically depends on conservation of this domain since ~90% of cancer-related P53 gene mutations are missense mutations in the DBD, resulting in the loss of DNA binding and hence affecting p53 function in cell cycle control [112].”